ID
45165
Descripción
Principal Investigator: Andrzej Krolewski, MD, PhD, Joslin Diabetes Center, Boston, MA, USA MeSH: Diabetic Nephropathies https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000302 A collection of patients with type-2 diabetes was collected at the Joslin Diabetes Center. Patients were categorized to a group of cases with diabetic nephropathy, and a group of controls with normoalbuminuria. From these groups, 173 cases and 177 controls were randomly selected for a genome-wide association study.
Link
Palabras clave
Versiones (2)
- 25/8/22 25/8/22 - Chiara Middel
- 12/10/22 12/10/22 - Adrian Schulz
Titular de derechos de autor
Andrzej Krolewski, MD, PhD, Joslin Diabetes Center, Boston, MA, USA
Subido en
12 de octubre de 2022
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs000302 Genetic Study on Nephropathy in Type-2 Diabetes
Subject - Consent Information
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent Information
- Subject - Sample Mapping
- The dataset contains general diabetes 2 phenotype information including participants' case/control status (case: ESRD or proteinuria or microalbuminuria and chronic kidney disease [CKD] stage 4 or 5; control: normoalbuminuria, CKD Stage 1 or 2, at least 3 years duration and HbA1c of at least 6%), hemoglobin A1c values at study begin, BMI values, age of diabetes onset and duration etc., and general demographic information.
Similar models
Subject - Consent Information
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent Information
- Subject - Sample Mapping
- The dataset contains general diabetes 2 phenotype information including participants' case/control status (case: ESRD or proteinuria or microalbuminuria and chronic kidney disease [CKD] stage 4 or 5; control: normoalbuminuria, CKD Stage 1 or 2, at least 3 years duration and HbA1c of at least 6%), hemoglobin A1c values at study begin, BMI values, age of diabetes onset and duration etc., and general demographic information.